Caplin Point is a fast-growing, fully integrated Pharmaceutical company with a dominant presence in Latin America, Francophone Africa, and a growing presence in the Regulated markets such as USA and EU. The company was established in 1990 to manufacture a range of ointments, creams, and other external applications. The Company was listed in 1994 following its Initial Public Offering (IPO), which was oversubscribed 117 times, the proceeds of which were deployed in setting up a manufacturing facility at Pondicherry.
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa, and Francophone Africa, along with a presence in the United States of America and European region.
Caplin Point has a Market Cap of ₹15,613 Crore. As of May 2025, the company has demonstrated strong financial performance with consistent growth across key metrics. Caplin Point Laboratories Ltd's net profit jumped 17.25% since last year same period to ₹142.57 Crore in Q4 FY2024-2025.
For the full fiscal year 2025, the company posted impressive results: Net profit increased by 17.33% to ₹536.31 Crore, with sales up 14.37% to ₹1,937.47 Crore. The company has maintained strong operational performance with Sales rose 10.86% to ₹502.45 Crore in the quarter ended March 2025, as against ₹453.22 Crore during the previous quarter ended March 2024.
Key financial highlights include:
- Net Profit: ₹536.31 Crore (FY 2025)
- Revenue: ₹1,937.47 Crore (FY 2025)
- Operating Profit Margin: 32.55% (FY 2025)
- Return on Equity: 18%
- Pre-tax Margin: 35%
The company is debt-free and has a strong balance sheet, enabling it to report stable earnings growth across business cycles. This financial strength has positioned the company well for continued growth and expansion initiatives.
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA, and other nations. The company offers a range of pharmaceutical products, with 4,000+ registered licenses and 650 formulations across 36 therapeutic areas. Its product line includes more than 65% of the drugs on the WHO essential drug list.
The company's extensive product portfolio encompasses various forms like tablets, capsules, injections, eye drops, oral liquids, soft gel capsules, ointments, creams, gels, injectable powders, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. The Company's product segments include Antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Pain Management, and Anti-ulcers.
The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa, and a USFDA/EU-GMP approved injectable facility.
Caplin Point operates multiple state-of-the-art manufacturing and research facilities across India. Caplin Steriles Limited, (CP-IV) is a US FDA, EU-GMP, INVIMA, and WHO-GMP approved manufacturing facility handling Sterile Injectable and Ophthalmic dosages. CP-V is a dedicated R&D facility for a wide range of products like Liquid Injectables in Vial and PFS presentations, Ophthalmic products, and Lyophilized products. This R&D facility especially caters to regulated markets like U.S. and Europe etc.
The company has also expanded its oncology capabilities with Caplin One Labs Limited, a wholly-owned subsidiary of Caplin Point Laboratories Limited, is pleased to announce the completion of its state-of-the-art Oncology facility at Kakkalur, near Chennai, and immediate commencement of operations.
The Company focused on the emerging markets of Latin America, Caribbean, Francophone and Southern Africa and is today one of the leading suppliers of Pharmaceuticals in these regions, with over 4000 product licenses across the globe. Company thrives on a unique business model of owning distribution networks, catering predominantly to the Bottom of the Pyramid, in the areas of its presence.
Recent strategic developments include Caplin Point acquires 100% stake in Mexican pharma firm Triwin Pharma for market expansion. This acquisition strengthens the company's presence in the Latin American market, a key growth region for Caplin Point.
Caplin Point has made significant strides in the regulated US market through its subsidiary Caplin Steriles. It has developed and filed 48 ANDAs in USA on its own and with partners, with 38 approvals so far. Recent approvals include Caplin Point Laboratories' subsidiary, Caplin Steriles, has received USFDA approval for Haloperidol Decanoate Injection, a generic treatment for schizophrenia, potentially entering a $16.4 million market.
The company continues to expand its US presence with Caplin Point Laboratories' subsidiary, Caplin Steriles, has received USFDA approval for Phytonadione Injectable Emulsion, expanding its presence in the U.S. generics market.
Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on May 15, 2025, inter alia, have recommended the dividend of ₹3 per equity Share (i.e., 150%), subject to the approval of the shareholders. Caplin Point Laboratories has fixed May 30, 2025, as the record date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.
The company has demonstrated strong shareholder value creation with Caplin Point Laboratories Ltd share price moved up by 173.37% on BSE over the last three years, reflecting investor confidence in the company's growth trajectory and business model.
The company has delivered good profit growth of 20.5% CAGR over the last 5 years and continues to maintain its debt-free status while pursuing strategic growth initiatives across its key markets.
